References

Rosacea Free Forever

Rosacea Free Forever Cure

Get Instant Access

1. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990;323:720-724.

2. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.

3. Chapman RM, Corcoran MM, Gardiner A, Hawthorn LA, Cowell JK, Oscier DG. Frequent homozygous deletions of the D13S25 locus in chromosome region 13q14 defines the location of a gene critical in leukaemogenesis in chronic B-cell lymphocytic leukaemia. Oncogene 1994;9:1289-1293.

4. Jabbar SA, Ganeshaguru K, Wickremasinghe RG, Hoffbrand AV, Foroni L. Deletion of chromosome 13 (band q14) but not trisomy 12 is a clonal event in B-chronic lymphocytic leukaemia (CLL). Br J Haematol 1995;90:476-478.

5. Garcia-Marco JA, Price CM, Catovsky D. Interphase cytogenetics in chronic lymphocytic leukemia. Cancer Genet Cytogenet 1997;94:52-58.

6. Cuneo A, Bigoni R, Rigolin GM, et al. 13q14 deletion in non-Hodgkin's lymphoma: correlation with clinico-pathologic features. Haematologica 1999;84:589-593.

7. Cuneo A, Bigoni R, Rigolin GM, et al. Cytogenetic profile of lymphoma of follicle mantle lineage: correlation with clinicobiologic features. Blood 1999;93:1372-1380.

8. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-49.

9. Avet-Louseau H, Daviet A, Sauner S, Bataille R. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol 2000;111:1116-1117.

10. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-1930.

11. Knuutila S, Teerenhovi L, Larramendy ML, et al. Cell lineage involvement of recurrent chromosomal abnormalities in hematologic neoplasms. Genes Chromosomes Cancer 1994;10:95-102.

12. Brown AG, Ross FM, Dunne EM, Steel CM, Weir-Thompson EM. Evidence for a new tumour suppressor locus (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nat Genet 1993;3:67-72.

13. Hawthorn LA, Chapman R, Oscier D, Cowell JK. The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 1993;8:1415-1419.

14. Liu Y, Szekely L, Grander D, et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: evidence for a role of an adjacent locus. Proc Natl Acad Sci U S A 1993;90:8697-8701.

15. Hawthorn L, Roberts T, Verlind E, Kooy RF, Cowell JK. A yeast artificial chromosome contig that spans the RB1-D13S31 interval on human chromosome 13 and encompasses the frequently deleted region in B-cell chronic lymphocytic leukemia. Genomics 1995;30:425-430.

16. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-330.

17. Bouyge-Moreau I, Rondeau G, Avet-Loiseau H, et al. Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3. Genomics 1997;46:183-190.

18. Corcoran MM, Rasool O, Liu Y, et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 1998;91:1382-1390.

19. Stilgenbauer S, Nickolenko J, Wilhelm J, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene 1998;16:1891-1897.

20. Liu Y, Corcoran M, Rasool O, et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia. Oncogene 1997;15:2463-2473.

21. Bezieau S, Devilder MC, Rondeau G, Cadoret E, Moisan JP, Moreau I. Assignment of 48 ESTs to chromosome 13 band q14.3 and expression pattern for ESTs located in the core region deleted in B-CLL. Genomics 1998;52: 369-373.

22. Kapanadze B, Kashuba V, Baranova A, et al. A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5. FEBS Lett 1998;426:266-270.

23. Mabuchi H, Fujii H, Calin G, et al. Cloning and characterization of CLLD6, CLLD7, and CLLD8, novel candidate genes for leukemogenesis at chromosome 13q14, a region commonly deleted in B-cell chronic lymphocytic leukemia. Cancer Res 2001;61:2870-2877.

24. Bullrich F, Fujii H, Calin G, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001;61:6640-6648.

25. Wolf S, Mertens D, Schaffner C, et al. B-cell neoplasia associated gene with multiple splicing (BCMS): the candidate B-CLL gene on 13q14 comprises more than 560 kb covering all critical regions. Hum Mol Genet 2001;10:1275-1285.

26. Sossey-Alaoui K, Kitamura E, Head K, Cowell JK. Characterization of FAM10A4, a member of the ST13 tumor suppressor gene family that maps to the 13q14.3 region associated with B-cell leukemia, multiple myeloma, and prostate cancer. Genomics 2002;80:5-7.

27. Kitamura E, Su G, Sossey-Alaoui K, et al. A transcription map of the minimally deleted region from 13q14 in B-cell chronic lymphocytic leukemia as defined by large scale sequencing of the 650 kb critical region. Oncogene 2000;19:5772-5780.

28. Rondeau G, Moreau I, Bezieau S, Cadoret E, Moisan JP, Devilder MC. Exclusion of Leu1 and Leu2 genes as tumor suppressor genes in 13q14.3-deleted B-CLL. Leukemia 1999;13:1630-1632.

29. Neilson JR, Auer R, White D, et al. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:1929-1932.

30. Hogan WJ, Tefferi A, Borell TJ, Jenkins R, Li CY, Witzig TE. Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999;110:77-81.

31. D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001;42:109-114.

32. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-146.

33. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-1184.

34. Gahrton G, Robert KH, Friberg K, Zech L, Bird AG. Extra chromosome 12 in chronic lymphocytic leukaemia. Lancet 1980;1:146-147.

35. Sadamori N, Han T, Minowada J, Cohen E, Sandberg AA. Chromosome studies in stimulated lymphocytes of B-cell chronic lymphocytic leukemias. Hematol Oncol 1983;1:243-250.

36. Han T, Sadamori N, Ozer H, et al. Cytogenetic studies in 77 patients with chronic lymphocytic leukemia: correlations with clinical, immunologic, and phenotypic data. J Clin Oncol 1984;2:1121-1132.

37. Losada AP, Wessman M, Tiainen M, et al. Trisomy 12 in chronic lymphocytic leukemia: an interphase cytogenetic study. Blood 1991;78:775-779.

38. Anastasi J, Le Beau MM, Vardiman JW, Fernald AA, Larson RA, Rowley JD. Detection of trisomy 12 in chronic lymphocytic leukemia by fluorescence in situ hybridization to interphase cells: a simple and sensitive method. Blood 1992;79:1796-1801.

39. Raghoebier S, Kibbelaar RE, Kleiverda JK, et al. Mosaicism of trisomy 12 in chronic lymphocytic leukemia detected by non-radioactive in situ hybridization. Leukemia 1992;6:1220-1226.

40. Cuneo A, Wlodarska I, Sayed Aly M, et al. Non-radioactive in situ hybridization for the detection and monitoring of trisomy 12 in B-cell chronic lymphocytic leukaemia. Br J Haematol 1992;81:192-196.

41. Dohner H, Pohl S, Bulgay-Morschel M, Stilgenbauer S, Bentz M, Lichter P. Trisomy 12 in chronic lymphoid leukemias—a metaphase and interphase cytogenetic analysis. Leukemia 1993;7:516-20.

42. Escudier SM, Pereira-Leahy JM, Drach JW, et al. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood 1993;81:2702-2707.

43. Crossen PE, Horn HL. Origin of trisomy 12 in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1987;28:185-186.

44. Einhorn S, Burvall K, Juliusson G, Gahrton G, Meeker T. Molecular analyses of chromosome 12 in chronic lymphocytic leukemia. Leukemia 1989;3:871-874.

45. Dierlamm J, Wlodarska I, Michaux L, et al. FISH identifies different types of duplications with 12q13-15 as the commonly involved segment in B-cell lymphoproliferative malignancies characterized by partial trisomy 12. Genes Chromosomes Cancer 1997;20:155-166.

46. Chena C, Sarmiento M, Palacios MF, Scolnik M, Slavutsky I. Dup(12)(q13-q22) and 13q14 deletion in a case of B-cell chronic lymphocytic leukemia. Acta Haematol 2000;104:197-201.

47. Huang YQ, Raphael B, Buchbinder A, Li JJ, Zhang WG, Friedman-Kien AE. Rearrangement and expression of MDM2 oncogene in chronic lymphocytic leukemia. Am J Hematol 1994;47:139-141.

48. Merup M, Juliusson G, Wu X, et al. Amplification of multiple regions of chromosome 12, including 12q13-15, in chronic lymphocytic leukaemia. Eur J Haematol 1997;58:174-180.

49. Watanabe T, Hotta T, Ichikawa A, et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994;84:3158-3165.

50. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387: 296-299.

51. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299-303.

52. Gahn B, Schafer C, Neef J, et al. Detection of trisomy 12 and Rb-deletion in CD34+ cells of patients with B-cell chronic lymphocytic leukemia. Blood 1997;89:4275-4281.

53. Gahn B, Schafer C, Neef J, et al. Detection of trisomy 12 in CD34+ progenitor cells in a patient with B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization. Ann Oncol 1997;8(suppl 2):55-57.

54. Gahn B, Wendenburg B, Troff C, et al. Analysis of progenitor cell involvement in B-CLL by simultaneous immunophenotypic and genotypic analysis at the single cell level. Br J Haematol 1999;105:955-959.

55. Han T, Ohtaki K, Sadamori N, et al. Cytogenetic evidence for clonal evolution in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1986;23:321-328.

56. Hjalmar V, Hast R, Kimby E. Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic leukemic B-cell disorders. Haematologica 2001;86:174-180.

57. Criel A, Wlodarska I, Meeus P, et al. Trisomy 12 is uncommon in typical chronic lymphocytic leukaemias. Br J Haematol 1994;87:523-528.

58. Cuneo A, Bigoni R, Balboni M, et al. Trisomy 12 in chronic lymphocytic leukemia and hairy cell leukemia: a cytogenetic and interphase cytogenetic study. Leuk Lymphoma 1994;15:167-172.

59. Garcia-Marco J, Matutes E, Morilla R, et al. Trisomy 12 in B-cell chronic lymphocytic leukaemia: assessment of lineage restriction by simultaneous analysis of immunophenotype and genotype in interphase cells by fluorescence in situ hybridization. Br J Haematol 1994;87:44-50.

60. Hjalmar V, Kimby E, Matutes E, et al. Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. Haematologica 1998;83:602-609.

61. Liso V, Capalbo S, Lapietra A, Pavone V, Guarini A, Specchia G. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia. Haematologica 1999;84:212-217.

62. Navarro B, Garcia-Marco JA, Jones D, Price CM, Catovsky D. Association and clonal distribution of trisomy 12 and 13q14 deletions in chronic lymphocytic leukaemia. Br J Haematol 1998;102:1330-1334.

63. Han T, Ozer H, Sadamori N, et al. Prognostic importance of cytogenetic abnormalities in patients with chronic lymphocytic leukemia. N Engl J Med 1984;310:288-292.

64. Sadamori N, Han T, Minowada J, Sandberg AA. Clinical significance of cytogenetic findings in untreated patients with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1984;11:45-51.

65. Juliusson G, Gahrton G. Poor age-corrected survival of chronic lymphocytic leukaemia patients with trisomy 12. Eur J Haematol 1987;38:315-317.

66. Pittman S, Catovsky D. Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia. Br J Haematol 1984;58:649-660.

67. Geisler CH, Philip P, Hansen MM. B-cell chronic lymphocytic leukaemia: clonal chromosome abnormalities and prognosis in 89 cases. Eur J Haematol 1989;43:397-403.

68. Han T, Sadamori N, Block AM, et al. Cytogenetic studies in chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia: a progress report. Nouv Rev Fr Hematol 1988;30:393-395.

69. Que TH, Marco JG, Ellis J, et al. Trisomy 12 in chronic lymphocytic leukemia detected by fluorescence in situ hybridization: analysis by stage, immunophenotype, and morphology. Blood 1993;82:571-575.

70. Knauf WU, Knuutila S, Zeigmeister B, Thiel E. Trisomy 12 in B-cell chronic lymphocytic leukemia: correlation with advanced disease, atypical morphology, high levels of sCD25, and with refractoriness to treatment. Leuk Lymphoma 1995;19:289-294.

71. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996;92:382-388.

72. Garcia-Marco JA, Price CM, Ellis J, et al. Correlation of trisomy 12 with proliferating cells by combined immunocy-tochemistry and fluorescence in situ hybridization in chronic lymphocytic leukemia. Leukemia 1996;10:1705-1711.

73. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997;89:4153-4160.

74. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-1854.

75. Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 1997;89:2516-2522.

76. Karhu R, Knuutila S, Kallioniemi OP, et al. Frequent loss of the 11q14-24 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. Genes Chromosomes Cancer 1997;19:286-290.

77. Nowell PC, Vonderheid EC, Besa E, Hoxie JA, Moreau L, Finan JB. The most common chromosome change in 86 chronic B cell or T cell tumors: a 14q32 translocation. Cancer Genet Cytogenet 1986;19:219-227.

78. Gahrton G, Juliusson G. Clinical implication of chromosomal aberrations in chronic B-lymphocytic leukaemia cells. Nouv Rev Fr Hematol 1988;30:389-392.

79. Koduru PR, Offit K, Filippa DA. Molecular analysis of breaks in BCL-1 proto-oncogene in B-cell lymphomas with abnormalities of 11q13. Oncogene 1989;4:929-934.

80. Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood 1991;78:259-263.

81. Brizard F, Dreyfus B, Guilhot F, Tanzer J, Brizard A. 11q13 rearrangement in B cell chronic lymphocytic leukemia. Leuk Lymphoma 1997;25:539-543.

82. Thieblemont C, Pack S, Sakai A, et al. Allelic loss of 11q13 as detected by MEN1-FISH is not associated with mutation of the MEN1 gene in lymphoid neoplasms. Leukemia 1999;13:85-91.

83. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders. Proc Natl Acad Sci USA 1996; 93:11,837-11,841.

84. Stilgenbauer S, Schaffner C, Litterst A, et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat Med 1997;3:1155-119.

85. Vorechovsky I, Luo L, Dyer MJ, et al. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. Nat Genet 1997;17:96-99.

86. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749-1753.

87. Pandita TK. ATM function and telomere stability. Oncogene 2002;21:611-618.

88. Siliciano JD, Canman CE, Taya Y, Sakaguchi K, Appella E, Kastan MB. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997;11:3471-3481.

89. Starostik P, Manshouri T, O'Brien S, et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 1998;58:4552-4557.

90. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999;94:748-753.

91. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999;353:26-29.

92. Bullrich F, Rasio D, Kitada S, et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res 1999;59:24-27.

93. Bevan S, Catovsky D, Marossy A, et al. Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia. Leukemia 1999;13:1497-1500.

94. Yuille MR, Condie A, Hudson CD, et al. ATM mutations are rare in familial chronic lymphocytic leukemia. Blood 2002;100:603-609.

95. Kobayashi H, Espinosa R, 3rd, Fernald AA, et al. Analysis of deletions of the long arm of chromosome 11 in hematologic malignancies with fluorescence in situ hybridization. Genes Chromosomes Cancer 1993;8:246-252.

96. Sembries S, Pahl H, Stilgenbauer S, Dohner H, Schriever F. Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood 1999;93:624-631.

97. Lens D, Matutes E, Catovsky D, Coignet LJ. Frequent deletions at 11q23 and 13q14 in B cell prolymphocytic leukemia (B-PLL). Leukemia 2000;14:427-430.

98. Cuneo A, Bigoni R, Rigolin GM, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance. Haematologica 2002;87:44-51.

99. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995;9:2003-2008.

100. Bigoni R, Cuneo A, Roberti MG, et al. Chromosome aberrations in atypical chronic lymphocytic leukemia: a cytogenetic and interphase cytogenetic study. Leukemia 1997;11:1933-1940.

101. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002;116:142-150.

102. Callet-Bauchu E, Salles G, Gazzo S, et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia 1999;13:460-468.

103. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991;88:5413-5417.

104. Fenaux P, Preudhomme C, Lai JL, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia 1992;6:246-250.

105. Gandini D, Aguiari GL, Cuneo A, Piva R, Castoldi GL, del Senno L. Novel small deletions of the p53 gene in late-stage B-cell chronic lymphocytic leukaemia. Br J Haematol 1994;88:881-885.

106. Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood 1997;89:2015-2023.

107. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.

108. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993;7:855-865.

109. Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1981.

110. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-357.

111. el Rouby S, Bayona W, Pisharody SM, Newcomb EW. p53 mutations in B-cell chronic lymphocytic leukemia. Curr Top Microbiol Immunol 1992;182:313-317.

112. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-3157.

113. Lens D, Dyer MJ, Garcia-Marco JM, et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 1997;99:848-857.

114. Barnabas N, Shurafa M, Van Dyke DL, Wolman SR, Clark D, Worsham MJ. Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer 2001;91:285-293.

115. el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993;82:3452-3459.

116. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-1589.

117. Geisler CH, Philip P, Christensen BE, et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. Leuk Res 1997;21: 1011-1023.

118. Philip P, Geisler C, Hansen MM, et al. Aberrations of chromosome 6 in 193 newly diagnosed untreated cases of chronic lymphocytic leukemia. Cancer Genet Cytogenet 1991;53:35-43.

119. Glassman AB, Harper-Allen EA, Hayes KJ, Hopwood VL, Gutterman EE, Zagryn SP. Chromosome 6 abnormalities associated with prolymphocytic acceleration in chronic lymphocytic leukemia. Ann Clin Lab Sci 1998; 28:24-29.

120. Stilgenbauer S, Bullinger L, Benner A, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999;13:1331-1334.

121. Cuneo A, Roberti MG, Bigoni R, et al. Four novel non-random chromosome rearrangements in B-cell chronic lymphocytic leukaemia: 6p24-25 and 12p12-13 translocations, 4q21 anomalies and monosomy 21. Br J Haematol 2000;108:559-564.

122. Offit K, Parsa NZ, Gaidano G, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma. Blood 1993;82:2157-2162.

123. Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: a sequential study of karyotypic instability in 51 patients. Am J Hematol 1998;59: 223-229.

124. Amiel A, Mulchanov I, Elis A, et al. Deletion of 6q27 in chronic lymphocytic leukemia and multiple myeloma detected by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;112:53-56.

125. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol 1997;97:107-112.

126. Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 1990;76:352-358.

127. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 1985;315:340-343.

128. Hernandez JM, Mecucci C, Criel A, et al. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia 1995;9:2140-2146.

129. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994;91:709-713.

130. Cuneo A, Bigoni R, Negrini M, et al. Cytogenetic and interphase cytogenetic characterization of atypical chronic lymphocytic leukemia carrying BCL1 translocation. Cancer Res 1997;57:1144-1150.

131. Adachi M, Cossman J, Longo D, Croce CM, Tsujimoto Y. Variant translocation of the bcl-2 gene to immunoglobulin lambda light chain gene in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989;86: 2771-2774.

132. Adachi M, Tefferi A, Greipp PR, Kipps TJ, Tsujimoto Y. Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med 1990;171:559-564.

133. Ueshima Y, Bird ML, Vardiman JW, Rowley JD. A 14;19 translocation in B-cell chronic lymphocytic leukemia: a new recurring chromosome aberration. Int J Cancer 1985;36:287-290.

134. Kerr LD, Duckett CS, Wamsley P, et al. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev 1992;6:2352-2363.

135. Michaux L, Mecucci C, Stul M, et al. BCL3 rearrangement and t(14;19)(q32;q13) in lymphoproliferative disorders. Genes Chromosomes Cancer 1996;15:38-47.

136. McKeithan TW, Takimoto GS, Ohno H, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer 1997; 20:64-72.

137. Juliusson G, Gahrton G. Chromosome aberrations in B-cell chronic lymphocytic leukemia. Pathogenetic and clinical implications. Cancer Genet Cytogenet 1990;45:143-160.

138. Virgilio L, Isobe M, Narducci MG, et al. Chromosome walking on the TCL1 locus involved in T-cell neoplasia. Proc Natl Acad Sci USA 1993;90:9275-9279.

139. Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994;91:12,530-12,534.

140. Narducci MG, Pescarmona E, Lazzeri C, et al. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res 2000;60:2095-2100.

141. Yuille MR, Condie A, Stone EM, et al. TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer 2001;30:336-341.

142. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 2002;99:6955-6960.

143. Geisler CH, Larsen JK, Hansen NE, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 1991;78:1795-1802.

144. Rassenti LZ, Kipps TJ. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med 1997;185: 1435-1445.

145. Lewis CM, Pegrum GD. Autoimmune antibodies in chronic lymphatic leukaemia. Br J Haematol 1978;38:75-84.

146. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986; 39:713-716.

147. Broker BM, Klajman A, Youinou P, et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J Autoimmun 1988;1:469-481.

148. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996;87:2615-2620.

149. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989;86:5913-5917.

150. Logtenberg T, Schutte ME, Inghirami G, et al. Immunoglobulin VH gene expression in human B cell lines and tumors: biased VH gene expression in chronic lymphocytic leukemia. Int Immunol 1989;1:362-366.

151. Mayer R, Logtenberg T, Strauchen J, et al. CD5 and immunoglobulin V gene expression in B-cell lymphomas and chronic lymphocytic leukemia. Blood 1990;75:1518-1524.

152. Deane M, Baker BW, Norton JD. Immunoglobulin VH4 gene usage in B lymphoid leukaemias. Br J Haematol 1993;84:242-249.

153. Ebeling SB, Schutte ME, Logtenberg T. Molecular analysis of VH and VL regions expressed in IgG-bearing chronic lymphocytic leukemia (CLL): further evidence that CLL is a heterogeneous group of tumors. Blood 1993;82:1626-1631.

154. Matolcsy A, Casali P, Nador RG, Liu YF, Knowles DM. Molecular characterization of IgA- and/or IgG-switched chronic lymphocytic leukemia B cells. Blood 1997;89:1732-1739.

155. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-1525.

156. Korganow AS, Martin T, Weber JC, et al. Molecular analysis of rearranged VH genes during B cell chronic lymphocytic leukemia: intraclonal stability is frequent but not constant. Leuk Lymphoma 1994;14:55-69.

157. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood 1995;85:1913-1919.

158. Schettino EW, Cerutti A, Chiorazzi N, Casali P. Lack of intraclonal diversification in Ig heavy and light chain V region genes expressed by CD5+IgM+ chronic lymphocytic leukemia B cells: a multiple time point analysis. J Immunol 1998;160:820-830.

159. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847.

160. Thompson AA, Talley JA, Do HN, et al. Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997;90:1387-1394.

161. Thompson AA, Do HN, Saxon A, Wall R. Widespread B29 (CD79b) gene defects and loss of expression in chronic lymphocytic leukemia. Leuk Lymphoma 1999;32:561-569.

162. Cragg MS, Chan HT, Fox MD, et al. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. Blood 2002;100:3068-3076.

163. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 1998;91:4694-4700.

164. Theml H, Love R, Begemann H. Factors in the pathomechanism of chronic lymphocytic leukemia. Annu Rev Med 1977;28:131-41.

165. Reed JC. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin Hematol 1998;35:3-13.

166. Schena M, Larsson LG, Gottardi D, et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981-2989.

167. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82:1820-1828.

168. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10:456-459.

169. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol 1996;156: 2624-2630.

170. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996;69:114-119.

171. Rechavi G, Katzir N, Brok-Simoni F, et al. A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia. Leukemia 1989;3:57-60.

172. Medeiros LJ, Van Krieken JH, Jaffe ES, Raffeld M. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990;76:2086-2090.

173. Dyer MJ, Zani VJ, Lu WZ, et al. BCL2translocations in leukemias of mature B cells. Blood 1994;83:3682-3688.

174. Adachi M, Tsujimoto Y. Juxtaposition of human bcl-2 and immunoglobulin lambda light chain gene in chronic lymphocytic leukemia is the result of a reciprocal chromosome translocation between chromosome 18 and 22. Oncogene 1989;4:1073-1075.

175. Tashiro S, Takechi M, Asou H, et al. Cytogenetic 2;18 and 18;22 translocation in chronic lymphocytic leukemia with juxtaposition of bcl-2 and immunoglobulin light chain genes. Oncogene 1992;7:573-577.

176. Laytragoon-Lewin N, Kashuba V, Mellstedt H, Klein G. bcl-2 rearrangement detected by pulsed-field gel electrophoresis (PFGF) in B-chronic lymphocytic leukemia (CLL) cells. Int J Cancer 1998;76:909-912.

177. Gottardi D, Alfarano A, De Leo AM, et al. In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996;94:612-618.

178. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998;91:3379-3389.

179. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96:393-397.

180. Pepper C, Bentley P, Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol 1996;95:513-517.

181. Molica S, Dattilo A, Giulino C, Levato D, Levato L. Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease. Haematologica 1998;83:1122-1124.

182. King D, Pringle JH, Hutchinson M, Cohen GM. Processing/activation of caspases, -3 and -7 and -8 but not caspase-2, in the induction of apoptosis in B-chronic lymphocytic leukemia cells. Leukemia 1998;12:1553-1560.

183. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996;92:97-103.

184. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998;91: 2387-2396.

185. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2663.

186. Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002;100:1795-1801.

187. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992;176: 1319-1326.

188. Konig A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997;11:258-265.

189. Tangye SG, Raison RL. Human cytokines suppress apoptosis of leukaemic CD5+B cells and preserve expression of bcl-2. Immunol Cell Biol 1997;75:127-135.

190. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 2001;113:400-406.

191. Frankfurt OS, Byrnes JJ, Villa L. Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. Leuk Res 1997;21:9-16.

192. Thomas A, El Rouby S, Reed JC, et al. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 1996;12:1055-1062.

193. Pepper C, Hoy T, Bentley DP. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997;76:935-938.

194. Pepper C, Thomas A, Hidalgo de Quintana J, Davies S, Hoy T, Bentley P. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia—the role of Bcl-2 family dysregulation. Leuk Res 1999;23:1007-1014.

195. Gottardi D, De Leo AM, Alfarano A, et al. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. Br J Haematol 1997;99:147-157.

196. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues—correlation with clinical course. Leukemia 1998;12:1230-1235.

197. Consoli U, El-Tounsi I, Sandoval A, et al. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 1998;91:1742-1748.

198. Zaja F, Di Loreto C, Amoroso V, et al. BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. Leuk Lymphoma 1998;28:567-572.

199. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16:1045-1052.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment